Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database

被引:1
|
作者
Han, Weiru [1 ]
Morris, Robert [2 ,3 ]
Bu, Kun [1 ]
Zhu, Tianrui [2 ]
Huang, Hong [4 ]
Cheng, Feng [2 ,3 ]
机构
[1] Univ S Florida, Coll Art & Sci, Dept Math & Stat, Tampa, FL 33620 USA
[2] Univ S Florida, Taneja Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33613 USA
[3] Univ S Florida, Coll Publ Hlth, Dept Biostat & Epidemiol, Tampa, FL 33613 USA
[4] Univ S Florida, Sch Informat, Tampa, FL 33620 USA
基金
美国国家卫生研究院;
关键词
pharmacovigilance; PubMed; adverse drug events; text comparison; FAERS Dashboard; DEMENTIA; MEDWATCH; PATIENT;
D O I
10.1139/cjpp-2024-0078
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The FDA Adverse Event Reporting System (FAERS) is a large-scale repository of reports concerning adverse drug events (ADEs). The same published clinical study or report may be reviewed by multiple companies or healthcare professionals and reported separately to the FDA, leading to a significant presence of duplicate reports in FAERS. These duplicate records can result in the identification of false associations between a given drug and an ADE. In this study, we first assessed the consistency of drug and ADE information in FAERS reports from Alzheimer's disease patients. Our findings showed greater congruence in drug-related information compared to ADE-related information, likely due to the greater heterogeneity and variety of terms or phrases used to describe ADEs. We then demonstrated that text comparison methods are effective in identifying duplicate records based on literature citations, testing 10 different comparison functions for their overall efficacy. Token-based methods (such as COSINE, QGRAM, and JACCARD), edit-based approaches (including OSA, LV, and DL), and sequence-based techniques like LCS have proven highly effective in accurately detecting identical publications within free text, demonstrating both high sensitivity and specificity. These results offer valuable insights for identifying duplicate FAERS reports and improving the reliability of detected associations between drugs and ADEs.
引用
收藏
页码:56 / 69
页数:14
相关论文
共 50 条
  • [41] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [42] SERIOUS ADVERSE DRUG EVENTS REPORTED TO THE FOOD AND DRUG ADMINISTRATION (FDA): ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) 2006-2011 DATABASE
    Sonawane, K. B.
    Hansen, R. A.
    VALUE IN HEALTH, 2015, 18 (03) : A86 - A86
  • [43] Asparaginase-related diabetic ketoacidosis: Analysis of the FDA Adverse Event Reporting System (FAERS) data and literature review
    Li, Dongxuan
    Gou, Jinghui
    Dong, Jie
    Dong, Yuzhu
    Xi, Xin
    Chen, Cheng
    Du, Qian
    Liu, Songqing
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (12) : 2176 - 2181
  • [44] Descriptive analysis of safety of ketamine utilizing FDA adverse events reporting system FAERS database
    Alamri, Khaled
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 499 - 499
  • [45] Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
    Zhao, Dan
    Zhang, Wangxin
    Liu, Yan
    Yan, Zhaojun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [46] Post-Marketing Surveillance of Polatuzumab Vedotin: A Disproportionality Analysis of the US FDA Adverse Event Reporting System (FAERS) Database
    Muscara, Claudia
    Allegra, Alessandro
    Tuccoli, Marco
    Flaccavento, Alessandra
    Cutroneo, Paola Maria
    DRUG SAFETY, 2024, 47 (12) : 1408 - 1408
  • [47] Real World Evidence of Chimeric T Cell Therapy Safety: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
    Ellithi, Moataz
    Elsallab, Magdi
    Lunning, Matthew
    D'Angelo, Christopher
    MOLECULAR THERAPY, 2023, 31 (04) : 726 - 727
  • [48] Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
    Ke, Chengjie
    Chen, Maohua
    Huang, Yaping
    Chen, Yan
    Lin, Cuihong
    Huang, Pinfang
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (07) : 5253 - 5264
  • [49] Safety profile analysis of Sunitinib and Dasatinib protein kinase inhibitors using FDA adverse event reporting system (FAERS) database
    Alyami, Fatimah
    Guo, Jeff J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 335 - 336
  • [50] EXISTENCE OF NOTORIETY BIAS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE AND ITS IMPACT ON SIGNAL STRENGTH
    Reddy, Ravindra N.
    Viswam, K. S.
    Thomas, B. E.
    Nair, G.
    Maheswari, E.
    Swaroop, A. M.
    VALUE IN HEALTH, 2019, 22 : S763 - S763